Fibroblast growth factor receptor 1

PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib

Retrieved on: 
Wednesday, August 30, 2023
Partnership, Fibroblast growth factor receptor 1, Therapy, Hepatocellular carcinoma, RCC, Survival, Cancer, Osteosarcoma, Biomarker, Messenger, Patient, PLOS, CDX, Ovarian cancer, PARP, HCC, Allar language, Renal cell carcinoma, Pharmaceutical industry

Data showed that the DRP®-Dovitinib CDx was able to identify a subgroup of advanced renal cell carcinoma (RCC) patients that have improved clinical benefit from treatment with dovitinib, as compared to unselected patients.

Key Points: 
  • Data showed that the DRP®-Dovitinib CDx was able to identify a subgroup of advanced renal cell carcinoma (RCC) patients that have improved clinical benefit from treatment with dovitinib, as compared to unselected patients.
  • “This is the first validated predictive biomarker in renal cell carcinoma, a long-standing goal in potentially improving the treatment of these patients.
  • An additional prospective trial would be required before RCC patients that are candidates for dovitinib can benefit from this diagnostic breakthrough.
  • In addition, in partnership with Allarity , Oncoheroes Biosciences has an ongoing program to develop dovitinib, together with the DRP®-dovitinib CDx, as a treatment for pediatric osteosarcoma.

Tyra Biosciences to Present at Upcoming Investor Conferences

Retrieved on: 
Thursday, November 10, 2022
Investor, Fibroblast growth factor receptor 1, Nasdaq, Cancer, SNP, Webcast, Fibroblast growth factor receptor, Chromosomal rearrangement, CA, FGFR4, Transfection, Company, Science, Conference, FGFR, Patient, CEO, FGFR3, Achondroplasia, FGFR2, RET, Pharmaceutical industry, Security (finance), Cholangiocarcinoma

Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.

Key Points: 
  • Webcasts of the fireside chats will be available via the For Investors page on the Investor section of the TYRA website.
  • Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • TYRA-200 is an FGFR1/2/3 inhibitor with potency against FGFR2 fusions, molecular brake mutations and gatekeeper resistance that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and RET (REarranged during Transfection kinase) driven cancers.

Tyra Biosciences Announces Planned Chief Financial Officer Transition

Retrieved on: 
Wednesday, November 2, 2022
Security (finance), Agricultural economics, Growth, Montana State University, FGFR3, Risk, CEO, Vinylcyclopropane rearrangement, Fibroblast growth factor receptor, MicroRNA, Acquisition, U.S. Securities and Exchange Commission, Annual report, Daiichi Sankyo, FGFR, SEC, Cancer, Esperies, Research, AbbVie, FGFR4, Regeneron Pharmaceuticals, Business administration, Esperion Therapeutics, IND, Nasdaq, COVID-19, FGFR2, Agriculture, Fibroblast growth factor receptor 1, Eli Lilly, SNP, CFO, Form 10-K, RET, Sale, PricewaterhouseCoopers, Private Securities Litigation Reform Act, Achondroplasia, Transfection, Therapy, FDA, Patient, Audit committee, Cooper, Science, CA, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022. TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition. 

Key Points: 
  • CARLSBAD, Calif., Nov. 2, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that its Chief Financial Officer, Esther van den Boom, will be stepping down to transition into an advisory role at the end of 2022.
  • TYRA also announced that Alan Fuhrman has been appointed as Chief Financial Officer effective January 1, 2023, and Ms. van den Boom will support the transition.
  • Prior to that, Mr. Fuhrman served as the Chief Financial Officer of Amplyx Pharmaceuticals, Inc. from December 2017 through June 2020.
  • "It has been my privilege to serve as Chief Financial Officer of TYRA since shortly after the company's inception," said Ms. van den Boom.

Global FLT3 Inhibitors Market Research Report 2022: Focus on Commercialized Therapy & Potential Pipeline Products - ResearchAndMarkets.com

Retrieved on: 
Friday, September 9, 2022
General Health, Pharmaceutical, Health, Investigational New Drug, Fibroblast growth factor receptor 1, NDA, Allar, Jerusalem, Cancer, Research, Abbreviated New Drug Application, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RCC, Therapy, IND, Benchmarking, AML, Incidence, New Drug Application, Novartis, Food, Renal cell carcinoma, Diagnosis, Acute myeloid leukemia, Investment, Region, Lymphatic system, Classification, FLT3, Daiichi Sankyo, Biology, FDA, CAGR, CRL, Adult, Crenolanib, Country, Name, Endpoint security, Industry, Drug development, Astellas Pharma, Growth, Patient, Pharmaceutical industry, Gilteritinib, Limited

The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FLT3 Inhibitors Market - A Global and Country Analysis: Focus on Commercialized Therapy, Potential Pipeline Product, and Region - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • The current study aims to assess the global FLT3 inhibitors market by focusing on the marketed and potential pipeline therapies.
  • Increasing investments in the research and development of drug manufacturing are one of the major opportunities in the global FLT3 inhibitors market.
  • The growing interest of the pharmaceutical industry in the therapeutic potential for treating blood cancers with FLT3 positive mutations has been a catalyst for the progress of the global FLT3 inhibitors market.

Tyra Biosciences to Participate at September 2022 Investor Conferences

Retrieved on: 
Thursday, September 8, 2022
CA, Achondroplasia, Cancer, Fibroblast growth factor receptor 1, SNP, FGFR, Fibroblast growth factor receptor, RET, LinkedIn, Science, FGFR4, Chromosomal rearrangement, Nasdaq, Transfection, FGFR2, FGFR3, Patient, Medical imaging, Pharmaceutical industry, Cholangiocarcinoma

CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

Key Points: 
  • CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:
    Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer.
  • Leveraging SNP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.
  • TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma.
  • TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers.

Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib

Retrieved on: 
Monday, January 3, 2022
MA, NDA, Cancer, Clinical trial, Cisplatin, FDA, File, RNA, Doxorubicin, Ixabepilone, Glioblastoma, RCC, Survival, Ovarian cancer, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Prostate cancer, Partnership, PARP, CEO, Therapy, PMA, Dana–Farber Cancer Institute, Patient, Nasdaq, Program, Adult, Drug development, Allar, Jerusalem, Renal cell carcinoma, Time, Literature, GBM, Osteosarcoma, Fibroblast growth factor receptor, Pharmaceutical industry, Fibroblast growth factor receptor 1

Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers.

Key Points: 
  • Under the terms of the licensing agreements, Oncoheroes acquires global, exclusive rights to fund and conduct further clinical development of both dovitinib and stenoparib in pediatric cancers.
  • Oncoheroes will take responsibility for pediatric cancer clinical development activities for both clinical-stage therapeutics.
  • If Allarity does not re-acquire the pediatric field rights, it will further receive certain clinical/regulatory milestone payments and royalties on sales of stenoparib and dovitinib in the pediatric cancer market from Oncoheroes.
  • Steve R. Carchedi, CEO of Allarity Therapeutics, commented, We are very pleased to partner with Oncoheroes Biosciences to advance both dovitinib and stenoparib as potential new therapeutic options for the personalized treatment of children and adolescents with cancer.

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

Retrieved on: 
Wednesday, December 22, 2021
NDA, Doxorubicin, U.S. Securities and Exchange Commission, Society for Integrative Oncology, RNA, Nasdaq, Ovarian cancer, Glioblastoma, Risk, Patient, Neoplasm, Private Securities Litigation Reform Act, PMA, Dean (education), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Biomedical sciences, Oncology, PARP, University, GIST, Forward-looking statement, Therapy, Ixabepilone, COVID-19, GBM, Hepatocellular carcinoma, Literature, Trial of the century, Cancer, Biopsy, Company, RCC, HCC, Stromal cell, Endometrial cancer, Gene expression, Food, File, Cisplatin, Clinical trial, Prostate cancer, Allare Allari, FDA, Security (finance), Renal cell carcinoma, Pharmaceutical industry, Medical imaging, Novartis, Fibroblast growth factor receptor 1

We greatly look forward to the approval of dovitinib and to introducing the clinical value of DRP companion diagnostics to oncologists and their patients.

Key Points: 
  • We greatly look forward to the approval of dovitinib and to introducing the clinical value of DRP companion diagnostics to oncologists and their patients.
  • Dovitinib is a small molecule, pan-tyrosine kinase inhibitor in-licensed from Novartis, and is Allaritys most advanced clinical therapeutic candidate.
  • The drug has previously shown clinical activity in a number of cancer indications, including RCC, gastrointestinal stromal tumors (GIST), endometrial cancer, metastatic breast cancer, and hepatocellular carcinoma (HCC).
  • I look forward to working with Allarity to advance this new personalized cancer care approach for RCC patients."

Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market

Retrieved on: 
Tuesday, December 21, 2021
Literature, Prostate cancer, Clinical trial, Exercise, FDA, Therapy, PMA, Doxorubicin, Trial of the century, PARP, Renal cell carcinoma, Glioblastoma, Cisplatin, PIPE, NDA, Security (finance), U.S. Securities and Exchange Commission, COVID-19, Warrant, Ovarian cancer, Nasdaq, Risk, Partnership, Ixabepilone, Private Securities Litigation Reform Act, Forward-looking statement, Company, SEC, Allare Allari, RNA, Cancer, GBM, Sale, Patient, LP, Pharmaceutical industry, Fibroblast growth factor receptor 1

A registration statement relating to the Recapitalization Share Exchange, filed previously with the Securities and Exchange Commission (SEC), became effective on November 5, 2021.

Key Points: 
  • A registration statement relating to the Recapitalization Share Exchange, filed previously with the Securities and Exchange Commission (SEC), became effective on November 5, 2021.
  • Copies of the registration statements can be accessed through the Securities and Exchange Commissions website at www.sec.gov .
  • LifeSci Capital acted as exclusive placement agent for the PIPE Investment.
  • Allarity Therapeutics, Inc. (Nasdaq: ALLR) develops drugs for personalized treatment of cancer guided by its proprietary and highly validated companion diagnostic technology, the DRP platform.

Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

Retrieved on: 
Thursday, September 16, 2021
PMA, Ovarian cancer, Fibroblast growth factor receptor, Food, NDA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FDA, European Society for Medical Oncology, Confidence interval, Forward-looking statement, Prostate cancer, Allar, Jerusalem, Sorafenib, Patient, ESMO, Confidence, Company, Fibroblast growth factor receptor 1, Nasdaq, Clinical trial, Disease, Renal cell carcinoma, Survival, Doxorubicin, Breast, Breast cancer, Irofulven, Progression-free survival, RNA, PARP, Cisplatin, Ixabepilone, Cancer, Social media, Goal, RCC, Oncology, Pharmaceutical industry

These results validate that the Dovitinib DRP companion diagnostic can identify RCC patients that benefit from treatment with dovitinib when compared to alternative treatment with sorafenib.

Key Points: 
  • These results validate that the Dovitinib DRP companion diagnostic can identify RCC patients that benefit from treatment with dovitinib when compared to alternative treatment with sorafenib.
  • The benefit of dovitinib therapy was also evident in progression-free survival data.
  • Allarity plans to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) for the approval of dovitinib for the treatment of RCC during Q4 2021.
  • We remain committed to bringing novel oncology therapeutics to market, and to patients, together with their DRP companion diagnostics to improve patient outcomes.

Eisai: MHLW Grants Orphan Drug Designation in Japan to Novel FGF Receptor Selective Tyrosine Kinase Inhibitor E7090

Retrieved on: 
Monday, February 22, 2021
Tyrosine kinase receptors, Clusters of differentiation, Branches of biology, Cell biology, Biology, Fibroblast growth factor receptor 2, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor, Fibroblast growth factor, Tyrosine kinase, Cholangiocarcinoma, Protein kinase inhibitor

In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.

Key Points: 
  • In Japan, a Phase I clinical trial of E7090 was conducted, and E7090 has been designated as the target drug for the SAKIGAKE Designation System of the MHLW for the treatment of unresectable biliary tract cancer.
  • Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2 and FGFR3.
  • et al., "Biliary tract cancer registry in Japan from 2008 to 2013", J Hepatobiliary Pancreat Sci., 2016, 23, 149-157.
  • (6) Arai Y. et al., "Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma", Hepatology, 2014, 59, 1427-1434.